The global market for pre-filled syringes (PFS) is on a steep upward trajectory, expected to more than double from $7.9 billion in 2023 to over $16 billion by 2030.1 This surge reflects the pharmaceutical industry’s continued shift toward biologics, biosimilars, and injectable therapies, as well as a growing demand for safe, accessible, and patient-friendly drug delivery systems. PFS technology has become a cornerstone of this modern drug delivery, offering greater patient convenience as well as improvements in dosing accuracy, sterility, and safety.
However, as demand grows and the market matures, so too does its complexity. The technical, regulatory, and operational requirements for PFS development and manufacturing are far more demanding than for conventional fill-finish processes. For pharmaceutical companies, especially those approaching Phase III or commercial readiness, choosing the right partner to navigate a web of these considerations can make the difference between a smooth launch and a costly delay. However, selecting an optimal contract manufacturing organization (CMO) that combines scientific expertise, process maturity, and capacity for growth can significantly reduce risk and accelerate the path to commercialization.
The Evolving Landscape of Pre-Filled Syringe Manufacturing
In recent years, the PFS market has shifted from small, niche applications to a global standard for injectable biologics. Innovations in biologic drug formulations, combined with advances in device design and automation, have made PFS systems a fundamental component in next-generation therapies.
Yet with this progress comes heightened expectations. While multi-product sites play an integral role in PFS manufacturing, facilities must ensure stringent control of particulates and contamination between products and processes, optimize drug-device compatibility, and comply with the evolving Annex 1 and cGMP regulations. Meanwhile, global supply chains have grown even more complex, highlighting the need for CMOs that not only meet quality standards but can also deliver supply assurance, flexibility, and resilience. And as more companies aim to onshore or nearshore production to overcome geopolitical and logistical challenges, the ability to work with a U.S.-based or North American manufacturing partner has become a competitive advantage.
What Defines a Strong PFS Manufacturing Partner
Selecting a partner for pre-filled syringe development and commercial manufacturing requires careful evaluation. In addition to simply providing capacity, the right CMO brings the scientific, regulatory, and operational foundation needed for long-term success.
Integrated Capabilities Across the Product Lifecycle
End-to-end biologics manufacturing expertise from drug product development and process design through aseptic fill-finish is critical to ensuring consistency and control. This integration minimizes risk during tech transfer, preserves institutional knowledge, and streamlines the timelines between clinical and commercial phases.
A partner that combines process development insight with commercial-scale PFS operations can confirm that what is developed at the lab scale can be replicated seamlessly at production scale. This level of alignment becomes critical when a therapy transitions from small-batch clinical runs to commercial volumes where many variables can affect performance and yield.
Proven Quality and Regulatory Systems
PFS manufacturing demands a culture of precision and compliance. Leading CMOs operate within a unified global quality system that enforces harmonized procedures, robust deviation management, and continuous improvement across sites.
This commitment to quality is especially vital for aseptic processing. As global regulators increase scrutiny on sterile manufacturing, a strong regulatory track record with successful inspections and adherence to evolving standards such as Annex 1 are essential. Additionally, a mature quality culture also fosters proactive risk management, demonstrating a partner’s ability to identify and mitigate issues before they impact supply.
Experienced and Stable Workforce
Behind every successful PFS product is a team of seasoned experts. And while technology and automation play a major role, human expertise remains indispensable. A workforce with deep biologics experience and long tenure offers valuable continuity, minimizing risk during scale-up and maintaining operational excellence even under tight timelines.
Operational Agility and Planning for Supply Assurance
In an environment where supply chain disruptions and fluctuating demand have become normal, precise forecasting and contingency planning are non-negotiable. A capable CMO partner builds flexibility into its operations, maintaining dual sourcing strategies, establishing raw material redundancies, and modeling multiple scenarios to anticipate future needs. This kind of forward-looking planning ensures that production continues smoothly even when market dynamics shift or certain materials become constrained.
Strategic Location and North American Access
For many pharmaceutical companies, proximity to regulatory agencies, suppliers, and key markets has become increasingly valuable. U.S.-based contract manufacturing companies and those expanding in North America offer advantages in speed, reduced transport risk, logistics resilience, and alignment with local regulatory expectations which have become important factors to strengthen domestic and regional supply chains.
How AbbVie Embodies the Qualities of a Leading PFS Manufacturing Partner
While many CMOs are expanding their capabilities to meet the market’s growing demand, AbbVie Contract Manufacturing has been delivering on these expectations for decades. Leveraging nearly 40 years of global manufacturing experience and a legacy of delivering high-quality biologics, AbbVie offers a blueprint for what a reliable, end-to-end PFS partner looks like.
End-to-End Biologics and PFS Expertise
AbbVie’s integrated model spans every stage of the manufacturing lifecycle from drug substance and process development to formulation and aseptic fill-finish. This integration offers seamless transitions between development phases, reducing the risk of delays or variability when scaling up for commercial manufacturing.
Proven Quality and Compliance
With a unified quality system spanning a collection of seven biologics and aseptic facilities, AbbVie maintains consistent standards and full regulatory alignment across all sites. Each facility functions as part of a coordinated network, applying harmonized processes and protocols designed to meet evolving global regulatory standards, including Annex 1 requirements.
North American Expansion
AbbVie’s Puerto Rico biologics facility, approved for both bulk drug substance and pre-filled syringe manufacturing, reflects the company’s commitment to expanding capacity and supporting the growing preference for U.S. and North American manufacturing. The site’s 38,000-square-meter footprint houses large scale cell culture suites, downstream purification systems, and automated PFS filling lines supported by advanced quality control systems. With over 16 years of global supply experience, this strategic North American presence helps AbbVie’s partners mitigate risk, reduce lead times, and secure supply within a resilient geographical framework.
Skilled Workforce and Planning Precision
With more than 600 professionals, many with over a decade of commercial biologics experience, AbbVie’s workforce provides hands-on experience in navigating the requirements for programs to achieve regulatory approval and long-term success. AbbVie’s forecasting and planning discipline, refined over decades of successful large-scale biologics launches, also enables stability, foresight, and proactive management of critical materials to deliver reliable supply from late-stage clinical trials through commercial launch.
Building Confidence in the Future of PFS Manufacturing
As the pre-filled syringe market expands, pharmaceutical and biotech companies face increasing pressure to secure partners who can deliver quality, scalability, and compliance, all while managing costs and timelines.
AbbVie exemplifies the type of CMO that defines this next generation of partnership. The combination of U.S.-based infrastructure, commercial experience, and end-to-end PFS capability offers a model for how the industry can meet the growing global demand safely, efficiently, and sustainably. Now is the time to align with a partner who has both the expertise and infrastructure to take your product from development through commercial manufacturing without compromise.
Learn more about how AbbVie Contract Manufacturing supports biologics and pre-filled syringe manufacturing.
